<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="370996">
  <stage>Registered</stage>
  <submitdate>29/06/2016</submitdate>
  <approvaldate>8/07/2016</approvaldate>
  <actrnumber>ACTRN12616000907448</actrnumber>
  <trial_identification>
    <studytitle>Tranexamic acid Trial Intravenous versus Intra articular Tranexamic acid in Primary Hip Arthroplasty: A Prospective Randomised Double Blinded non Inferiority Trial</studytitle>
    <scientifictitle>  Effect of  Intravenous versus Intra articular Tranexamic acid on haemoglobin levels in patients undergoing primary Hip Arthroplasty A randomised Double blinded non inferiority trial. .
</scientifictitle>
    <utrn>U1111-1184-8157</utrn>
    <trialacronym>Tranexamic acid in Hip study IV versus Intra articular.
TAHIVIA</trialacronym>
    <secondaryid>NONE</secondaryid>
    <secondaryid>NONE</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Osteoarthritis </healthcondition>
    <conditioncode>
      <conditioncode1>Surgery</conditioncode1>
      <conditioncode2>Surgical techniques</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Osteoarthritis</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>At Induction patients are randomised into Group A or B.
Group A 15mg /kg IV infusion of Tranexamic acid given IV at induction and then at 8 hours and 16 hours post surgery.
Group B Intra articular dose of Tranexamic acid given in 40 mls of Normal Saline at 15mg.kg into the capsule prior to skin closure then followed by Normal Saline 100mls at 8 and 16 hours post surgery.</interventions>
    <comparator>This is a site control either IV or intra articular using equivalent dose.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change in Haemaglobin pre surgery and day 1 post surgery using normal pathology conducted Completed Blood Count assay.</outcome>
      <timepoint>1 week prior to surgery and 24 hours post surgery.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Number of transfusions, assessed by review of medical record.</outcome>
      <timepoint>24hours post surgery</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>DVT symptoms, any infections</outcome>
      <timepoint>Clinic visit at 6 weeks post surgery, phone contact at 90 days post surgery.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome> Days recorded of hospital stay electronically recorded by admission to discharge date</outcome>
      <timepoint>Discharge day</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Primary Hip arthroplasty due to osteoarthritis</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Pregnant and lactating women.
Renal Impairment (Creatinine&gt; 120mmol/L)
Active intravascular clotting or DVT tendencies.
Cognitive impairment.
Hypersensitivity to Tranexamic acid.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Sealed Opaque envelopes with numbered allocations using a digital randomised computer generated allocation Research staff blinded to which group patient would be allocated.</concealment>
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods>Summary statistics comparing the two groups using continuous variables and one way analysis with p value of &lt;0.05 considered. For a haemoglobin non inferiority margin of 5g/L a minimum of 85 patients  are required per group to achieve 90% power.
</statisticalmethods>
    <masking1>False</masking1>
    <masking2>True</masking2>
    <masking3>False</masking3>
    <masking4>False</masking4>
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3 / Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>17/06/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>85</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA</recruitmentstate>
    <hospital>Calvary Wakefield Hospital - Adelaide</hospital>
    <postcode>5000 - Adelaide</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>David Campbell</primarysponsorname>
    <primarysponsoraddress>Wakefield Orthopaedic Clinic, 270 Wakefield St L2 Adelaide SA 5000</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Other</fundingtype>
      <fundingname>Wakefield Orthopaedic Clinic</fundingname>
      <fundingaddress>270 Wakefield St L2, Adelaide SA 5000</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a randomised study to determine dosing methods  of administering Tranexamic acid  a drug used to  reduce bleeding in Hip replacement surgery. The purpose of the study is to determine if the drug is as effective giving it via Intravenous route or Intra articular route direct into the hip capsule. </summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Calvary Health Care Ethics Committee</ethicname>
      <ethicaddress>89 Strangways Tce North Adelaide 5006 South Australia</ethicaddress>
      <ethicapprovaldate>15/04/2016</ethicapprovaldate>
      <hrec>16 CHREC-F001</hrec>
      <ethicsubmitdate>25/03/2016</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>David Campbell</name>
      <address>Wakefield Orthopaedic Clinic, 270 Wakefield St L2,
Adelaide 
South Australia 5000</address>
      <phone>+ 61 882364128</phone>
      <fax />
      <email>dcampbell@woc.com.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>christine schutz</name>
      <address>Wakefield Orthopaedic Clinic
270 Wakefield St L2,
Adelaide 5000
SA</address>
      <phone>+61 882364128</phone>
      <fax />
      <email>cschutz@woc.com.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>christine schutz</name>
      <address>Wakefield Orthopaedic Clinic
270 Wakefield St L2 ,
Adelaide 
SA 5000</address>
      <phone>+61 882364128</phone>
      <fax />
      <email>cschutz@woc.com.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>christine Schutz</name>
      <address>270 Wakefield St L2
Adelaide 
South Australia 5000</address>
      <phone>0882364128</phone>
      <fax />
      <email>cschutz@woc.com.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>